Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

108.32 +0.86 (+0.80%)
Streaming Delayed Price Updated: 9:30 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday ↗
The company's recent past featured robust growth, and it anticipates continued rises into the near future. 
Via The Motley Fool
News headline image
Glaukos (GKOS) Q3 2025 Earnings Call Transcript ↗
Glaukos (GKOS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Expert Outlook: Glaukos Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Glaukos Stock Jumped Over 20% After-Hours Today ↗
Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance. 
Via Stocktwits
News headline image
What's going on in today's after hours session ↗
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Glaukos Corp (NYSE:GKOS) Soars on Strong Q3 2025 Earnings Beat and Robust 2026 Outlook ↗
Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance. 
Via Chartmill
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Expert Outlook: Glaukos Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Glaukos (GKOS) Q2 Revenue Jumps 30% ↗
Via The Motley Fool
News headline image
What 11 Analyst Ratings Have To Say About Glaukos ↗
 
Via Benzinga
News headline image
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Forecasting The Future: 7 Analyst Projections For Glaukos ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery ↗
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential. 
Via Benzinga
News headline image
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
News headline image
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition ↗
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model. 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.